BSE Live
Dec 05, 16:01Prev. Close
6470.60
Open Price
6470.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 05, 15:54Prev. Close
6469.00
Open Price
6467.00
Bid Price (Qty.)
6473.50 (6)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Divis Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 53.09 | 53.09 | 53.09 | 53.09 | 53.09 | |
| Total Share Capital | 53.09 | 53.09 | 53.09 | 53.09 | 53.09 | |
| Reserves and Surplus | 7,256.83 | 6,904.06 | 5,871.71 | 5,304.30 | 4,240.21 | |
| Total Reserves and Surplus | 7,256.83 | 6,904.06 | 5,871.71 | 5,304.30 | 4,240.21 | |
| Total Shareholders Funds | 7,309.92 | 6,957.15 | 5,924.80 | 5,357.39 | 4,293.31 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | |
| Deferred Tax Liabilities [Net] | 273.96 | 221.18 | 192.68 | 126.39 | 77.27 | |
| Other Long Term Liabilities | 4.47 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 20.52 | 13.17 | 14.95 | 15.30 | 11.57 | |
| Total Non-Current Liabilities | 298.95 | 234.35 | 207.63 | 141.69 | 89.30 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 33.63 | 105.60 | 63.11 | 35.74 | 41.42 | |
| Trade Payables | 590.72 | 492.26 | 411.21 | 445.80 | 232.69 | |
| Other Current Liabilities | 300.02 | 247.78 | 175.46 | 176.63 | 243.22 | |
| Short Term Provisions | 2.46 | 1.11 | 0.94 | 1.28 | 2.17 | |
| Total Current Liabilities | 926.83 | 846.75 | 650.72 | 659.45 | 519.50 | |
| Total Capital And Liabilities | 8,535.70 | 8,038.25 | 6,783.15 | 6,158.53 | 4,902.12 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 2,778.25 | 2,083.72 | 1,989.64 | 1,555.93 | 1,435.84 | |
| Intangible Assets | 3.60 | 4.05 | 6.55 | 3.26 | 2.93 | |
| Capital Work-In-Progress | 919.69 | 491.91 | 119.76 | 443.57 | 263.91 | |
| Fixed Assets | 3,701.54 | 2,579.68 | 2,115.95 | 2,002.76 | 1,702.68 | |
| Non-Current Investments | 0.01 | 547.26 | 0.01 | 0.01 | 0.01 | |
| Deferred Tax Assets [Net] | 4.38 | 2.34 | 1.03 | 3.56 | 4.14 | |
| Long Term Loans And Advances | 35.32 | 34.04 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 114.62 | 224.88 | 131.04 | 141.69 | 168.24 | |
| Total Non-Current Assets | 3,855.87 | 3,388.20 | 2,248.03 | 2,148.02 | 1,875.07 | |
| CURRENT ASSETS | ||||||
| Current Investments | 971.35 | 1,398.34 | 1,889.28 | 1,630.72 | 802.85 | |
| Inventories | 1,863.86 | 1,772.34 | 1,350.67 | 1,319.91 | 1,207.83 | |
| Trade Receivables | 1,413.35 | 1,163.37 | 1,014.36 | 900.92 | 880.92 | |
| Cash And Cash Equivalents | 122.63 | 115.26 | 112.46 | 78.70 | 73.43 | |
| Short Term Loans And Advances | 0.09 | 0.11 | 0.17 | 0.27 | 0.13 | |
| OtherCurrentAssets | 308.55 | 200.63 | 168.18 | 79.99 | 61.88 | |
| Total Current Assets | 4,679.83 | 4,650.05 | 4,535.12 | 4,010.51 | 3,027.04 | |
| Total Assets | 8,535.70 | 8,038.25 | 6,783.15 | 6,158.53 | 4,902.12 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,222.84 | 1,031.35 | 502.90 | 537.81 | 275.77 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 39.67 | 39.67 | 39.67 | 39.67 | 39.67 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 547.25 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 971.35 | 1,398.34 | 1,889.28 | 1,630.72 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 802.85 |
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Neutral Divis Laboratories; target of Rs 6925: Motilal Oswal
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill